Beth Israel Deaconess Medical Center
Dr. McDermott has been involved in clinical and translational cancer research for more than 20 years. He runs a large academic practice that focuses on patients with kidney cancer and melanoma and is the Chief of Medical Oncology at Beth Israel Deaconess Medical Center. As a clinical investigator, he and his colleagues in the IOP have led numerous trials that have made a significant impact in the care of patients with kidney cancer and melanoma. They have contributed to the FDA approval and rational application of cytokines (e.g., interleukin-2 and interferon), immune check point inhibitors (ICIs) (e.g., CTLA-4, PD-1/PD-L1 antibodies) and molecularly targeted therapies (e.g., bRAF, VEGF and HIF2 inhibitors). In recent years, he has worked with collaborators to define the role of novel endpoints (e.g., treatment-free survival) in cancer clinical trials. As a translational investigator, Dr. McDermott has focused his research on interrogating tumor samples to develop novel therapies and predictive biomarkers. Since 2012, he has been the Leader of the DF/HCC Kidney Cancer Program and co-Program Director of the DF/HCC Kidney Cancer SPORE with Dr. William Kaelin.
Disclosure information not submitted.